Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Oncology
Vol. 2, Issue 2, 2015April 27, 2015 EDT

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia

Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe, Susan J. Blalock,
oncology hematology treatment interruption tyrosine kinase inhibitors chronic myeloid leukemia
Copyright Logoccby-4.0 • https://doi.org/10.36469/9899
JHEOR
1.
Ward MA, Fang G, Richards KL, et al. Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia. JHEOR. 2015;2(2):181-191. doi:10.36469/9899
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)

View more stats

Powered by Scholastica, the modern academic journal management system